BioSpace, March 9, 2026: In April 2026 FDA will hold its first Advisory Committee meeting on cancer drugs in 9 months — the first one in FY 2026. It will discuss 2 AstraZeneca applications, one for a new drug for HR-positive HER2-negative breast cancer and the other for Truqap to treat metastatic hormone-sensitive prostate cancer.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Prasad Out At FDA, Turning Critics’ Focus Back To Makary
Inside Health Policy, March 6, 2026: FDA’s biologics chief Vinay Prasad is leaving FDA for the second time. This time his rejection of Uniqure and other rare disease treatments angered industry and some rare disease patients, and Members of Congress. But NCHR’s Zuckerman says Prasad’s focus on evidence strengthened FDA and will be missed.
Read More »Divisive F.D.A. Vaccine Regulator Is Resigning
New York Times, March 6, 2026: FDA’s biologics chief Vinay Prasad is resigning, leaving FDA for the second time. This time his rejection of rare disease treatments angered industry, some rare disease patients, and Members of Congress. But NCHR’s Diana Zuckerman says Prasad’s focus on evidence was welcomed by researchers and advocates who were concerned about FDA’s approval of ineffective treatments.
Read More »FDA’s Hoeg Reportedly Trying To Hire Friend, Fellow Antidepressant Skeptic
BioSpace, March 5, 2026: FDA’s CDER Director Tracy Beth Høeg wants to hire her friend Adam Urato, whose citizen’s petition urges a boxed warning on the risks of SSRIs during pregnancy. Diana Zuckerman and others say Høeg’s work has no nuance and doesn’t want to hear differences of opinion.
Read More »Edwards’ request for broader TAVR Medicare coverage gets pushback
MedTech Dive, January 28, 2026: MedTech Dive quotes public comments to CMS for and against Medicare coverage of TAVR for asymptomatic patients, including NCHR’s and Steve Woloshin’s criticism of the published evidence and medical society support
Read More »